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Abstract
Objectives—Accumulating evidence suggests that energy imbalance plays a role in pancreatic
carcinogenesis. However, it remains unclear whether single nucleotide polymorphisms (SNPs) in
genes regulating energy homeostasis influence pancreatic cancer risk. We investigated this
question in a case-control study conducted from 1994 to 1998.
Methods—Cases (n=173) were ascertained from hospitals in the Twin Cities and Mayo Clinic,
Minnesota. Controls (n=476) were identified from the general population and frequency matched
to cases by age and sex. Seven SNPs were evaluated in relation to pancreatic cancer using
unconditional logistic regression.
Results—After adjustment for confounders, the leucine/proline or proline/proline genotype of
the neuropeptide Y (NPY) gene rs16139 was associated with a lower risk than the leucine/leucine
genotype [odds ratio (OR) (95% confidence interval) (95% CI): 0.40 (0.15, 0.91)]. Conversely, an
increased risk was observed for the glycine/arginine or arginine/arginine genotype of the
adrenoceptor beta 2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine
genotype [OR (95% CI): 1.52 (1.01, 2.31)].
Conclusions—This study first reveals that SNPs in genes modulating energy intake (NPY) and
energy expenditure (ADRB2) altered pancreatic cancer risk. If confirmed by other studies, our
findings may shed new light on the etiology and prevention of pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is among the leading causes of cancer death in the United States and many
other countries.1,2 Worldwide, it is estimated that there are 227,000 deaths per year from this
disease.3 The etiology of pancreatic cancer is poorly understood, with cigarette smoking as
one of the few established risk factors.4 Primary prevention is particularly important for this
disease because it is rapidly fatal and there is no population screening test available for early
detection.5 To prevent pancreatic cancer, it is important to elucidate its genetic and
environmental causes.
Several lines of experimental and epidemiologic evidence suggest that energy imbalance is
implicated in pancreatic carcinogenesis. Calorie restriction has inhibited the development of
carcinogen-induced tumors in various animal models of cancer,6 and in humans, a reduced
risk of pancreatic cancer was observed in individuals of shorter than median stature who
were exposed to energy restriction during adolescence in the period of the Economic
Depression in the Netherlands.7 Obesity develops as a consequence of long-term positive
energy imbalance.8 Obesity, physical inactivity, and type-2 diabetes have been associated
with an increased risk of pancreatic cancer in most epidemiologic studies.8–12 A potential
mechanism underlying these associations is insulin resistance,8,12 and the results of cohort
studies showing that subjects with high serum levels of insulin and glucose (biomarkers of
insulin resistance) are more likely to develop pancreatic cancer supports this view.5,13
A number of genes involved in the central and peripheral regulation of energy homeostasis
have been identified.14–16 Given the substantial experimental and epidemiologic evidence
linking energy imbalance to the occurrence of pancreatic cancer, it is biologically plausible
that polymorphisms in genes modulating energy intake and energy expenditure influence the
risk of this malignancy. To date, few epidemiologic studies have investigated this
hypothesis. Therefore, we sought to evaluate the associations between genetic variability in
energy metabolism and the risk of pancreatic cancer in a population-based case-control
study.
MATERIALS AND METHODS
Study Population
A case-control study was conducted from April 1994 to September 1998 in Minnesota and
has been described in detail elsewhere.17,18 Briefly, cases were persons who were diagnosed
with pathologically-confirmed cancer of the exocrine pancreas (International Classification
of Disease for Oncology, third edition, code C25). The cases were recruited from all
hospitals in the seven-county metropolitan area of the Twin Cities (Minneapolis and St.
Paul) and the Mayo Clinic and those ascertained from the Mayo Clinic were confined to
residents in the Upper Midwest of the United States. Because a high proportion of patients
with pancreatic cancer die soon after diagnosis, an ultra-rapid case-ascertainment system
was adopted to quickly contact cases. As a result, the median number of days between
diagnosis and first contact for the study was only 13 days. Patients with pancreatic cancer
were eligible for the study if they were 20 years of age or older, English-speaking, and
mentally competent to give informed consent. Of 460 eligible cases identified during the
study period, 202 did not participate in the study due to occurrence of death before contact
or interview (n = 85), refusal of cases (n = 79), refusal of physicians (n = 31), and inability
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to contact cases (n = 7). After these exclusions, 258 cases participated in the study,
producing a response rate of 56% among those identified.
The source population of the study was Upper Midwest of the United States and potential
controls were randomly recruited from residents of the seven-county metropolitan area of
the Twin Cities. Names were selected from the drivers’ license and State identity card
databases for subjects aged 20–64 years and from the Health Care Financing Administration
(now called the Centers for Medicare and Medicaid Services) records for those aged 65
years or older. Controls were frequency matched to cases by age (within 5 years) and sex.
Inclusion criteria for controls were the same as those for cases, with an exception of
diagnosis of pancreatic cancer. A total of 1,141 eligible controls were identified, and 676 of
them participated in the study, yielding a response rate of 59%. Of the 934 subjects (258
cases and 676 controls) who completed at least some portion of the study, genotyping data
were not available for 259 subjects (69 cases and 190 controls) because they did not donate
a blood sample or had an insufficient amount of remaining DNA samples for genotyping
selected polymorphisms in the present study. Exclusion of subjects without the genotyping
data resulted in 189 cases and 486 controls that had data required for the analysis of the
present study. Of these subjects, only 16 cases and 10 controls were not of European descent
and were excluded to avoid potential population stratification. Therefore, a total of 173 cases
and 476 controls were available for the current analysis. Written, informed consent was
obtained from all study participants prior to their interview. The protocol for this case-
control study was approved by the Institutional Review Boards of the University of
Minnesota and the Mayo Clinic.
Data Collection—Cases and controls were interviewed in person to collect information on
demographics, education level attained, physical activity, medical history, and cigarette
smoking. Subjects were asked to report a history of type 2 diabetes mellitus. Since incident
diabetes that occurs less than 2 years prior to pancreatic cancer can be a symptom of
pancreatic cancer,19,20 subjects diagnosed with diabetes less than 2 years before their cancer
diagnosis (cases) or selection dates (controls) were treated as not having diabetes. During
the interview, usual diet of cases and controls was assessed by a slightly modified version of
the Willett food frequency questionnaire (FFQ), a validated dietary assessment instrument
widely used in nutritional epidemiologic studies.21 Calculating intakes of energy and
nutrients was based on the responses of subjects on all food items listed in the modified
Willet FFQ and a nutrient database developed for the Minnesota Colon Cancer Prevention
Research Unit studies. As a section of the FFQ used, habitual consumption of alcoholic
beverages (including wine, beer, and liquor) was estimated in the same way as intake of
energy and nutrients.
Genotyping
DNA samples were extracted from peripheral blood lymphocytes with a commercial kit
(Qiagen Inc., Valencia, CA). The single nucleotide polymorphisms (SNPs) considered in
this study were leptin (LEP) (rs7799039), leptin receptor (LEPR) (rs1137101), ghrelin/
obestatin prepropeptide (GHRL) (rs696217), neuropeptide Y (NPY) (rs16139), adrenoceptor
beta 2, surface (ADRB2) (rs1042713), adrenoceptor beta-3 (ADRB3) (rs4994), and
uncoupling protein 3 (mitochondrial, proton carrier) (UCP3) (rs1800849). These SNPs were
selected because 1) their genes regulate energy intake (LEP, LEPR, GHRL, and NPY) or
energy expenditure (ADRB2, ADRB3, and UCP3),14,15,22 2) they have established or
potential functional impact;14,23–30 the five of the seven selected SNPs are missense
mutations (rs7799039 and rs1800849 are not missense), and 3) they are common (minor
allele frequency >5%) among European Americans (the NCBI SNP database: http://
www.ncbi.nlm.nih.gov). SNP genotyping was conducted with TaqMan SNP Genotyping
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Assays (Life Technology, Grand Island, NY) in a laboratory (Fred Kadlubar, PhD) of the
Division of Medical Genetics, University of Arkansas for Medical Sciences. To minimize
genotyping error, several quality control measures were taken that include the blinding of
genotyping personnel to the case-control status of DNA samples and a random replication of
10% of the tested samples. The concordance was found to be 100% for the replicated
samples.
Statistical Analysis
All measured SNPs were tested for their deviation from the Hardy-Weinberg equilibrium
among controls. The demographic, lifestyle, and other characteristics of cases and controls
were compared using the t-test for continuous variables and the chi-square test for
categorical variables. The associations between genotyped SNPs and pancreatic cancer risk
were evaluated by unconditional logistic regression analysis. With subjects who were
homozygous for wild-type alleles of a SNP as the referent category, odds ratios (OR) and
95% confidence interval (95% CI) were estimated for those who were heterozygous or
homozygous for variant alleles. Considering the relatively small number of cases (n=173),
individuals who carried one or two copies of variant alleles were combined into one
category to improve the precision of risk estimates. To investigate the independent effect of
measured SNPs on pancreatic cancer risk, age, sex, education (three levels), cigarette
smoking (never, former, and current), and alcohol intake (servings/week) were added as
covariates to logistic regression models.
Haplotype analysis was not performed because none of the seven SNPs examined were
correlated with each other (all r2 ≤0.002) and only two SNPs (rs7799039 and rs16139) are
on the same chromosome (#7). The potential interactions of these SNPs with lifestyle factors
that could influence energy balance and insulin resistance (i.e. physical activity and dietary
intake of energy, fat, and fiber)31 were evaluated in relation to the risk of pancreatic cancer.
The statistical significance of interaction terms was assessed with the likelihood ratio test.
All statistical analyses were conducted with SAS (version 9.3; SAS Institute, Inc., Cary,
NC). Given that only seven SNPs were evaluated in our study and that all of these genetic
variants have established or potential functionality, the significance level (type I error) for
the associations between genotyped SNPs and pancreatic cancer risk was not corrected for
multiple comparisons. A two-sided p-value of <0.05 was considered statistically significant.
RESULTS
Demographic, lifestyle, and other characteristics of cases and controls were compared
(Table 1). The mean age of cases and controls was 66.2 years and 65.6 years, respectively.
Males constituted 59.9% of cases and 56.9% of controls. Cases were statistically
significantly less educated and physically inactive than controls, whereas history of type 2
diabetes was more common in cases than in controls.
All SNPs examined in this study were in Hardy-Weinberg equilibrium (all p>0.28), which
offers evidence supporting the accuracy and validity of the genotyping procedure. The
results for pancreatic cancer risk in relation to measured SNPs were presented in Table 2.
After adjustment for age, sex, education, smoking status, and alcohol intake, individuals
who were heterozygous [leucine (Leu)/proline (Pro)] or homozygous (Pro/Pro) for the
variant allele of NPY rs16139 experienced a 60% lower risk of pancreatic cancer than those
who were homozygous for the wild-type allele [OR (95% CI): 0.40 (0.15, 0.91)].
Conversely, a significantly increased risk was observed for subjects who harbored one or
two copies of the variant allele of ADRB2 rs1042713 [OR (95% CI): 1.52 (1.01, 2.31) for
glycine (Gly)/Arginine (Arg) and Arg/Arg vs. Gly/Gly]. Other SNPs analyzed in this study
were not significantly associated with the risk of pancreatic cancer. Adjustment for age only
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virtually did not alter the risk estimates for all selected SNPs that were obtained from
models without adjustment for any covariates. In addition, no statistically significant
interactions were observed on the disease risk for any combinations of the genotyped SNPs
and lifestyle factors considered.
DISCUSSION
In this population-based case-control study, we found that genetic variability in the
regulation of energy balance was associated with a statistically significant change in
pancreatic cancer risk. To our knowledge, the significant associations between
polymorphisms NPY rs16139 and ADRB2 rs1042713 and the risk of pancreatic cancer have
not been reported in previous epidemiologic studies.
Recent advances in human genomics have identified genes implicated in the central and
peripheral regulation of energy homeostasis.14,15,22 The genes that control food intake
include peripheral signal peptides (e.g., LEP and GHRL), central neuropeptides (e.g., NPY),
and their corresponding receptors.14 Some of the genes that modulate energy expenditure
are ADRB2, ADRB3, and UCP3.14 It is reasonable to hypothesize that functional
polymorphisms in these genes governing energy balance are associated with pancreatic
cancer risk through their effects on obesity and resultant insulin resistance. However, this
hypothesis has not been investigated in previous epidemiologic studies.
NPY is an appetite stimulator secreted in the hypothalamus and is regulated by the feedback
of ghrelin and leptin. While ghrelin stimulates appetite during fasting, leptin is released after
eating.14 A nonsynonymous SNP (rs16139) in the NPY gene results in an amino acid change
from Leu to Pro at codon 7 (Leu7Pro).29 A study of 14 healthy Caucasian men showed that
carriers of the Pro7-allele exhibited elevated plasma levels of NPY compared with
noncarriers.32 In a Dutch study, male carriers of the Pro7-allele had higher leptin levels and
BMI values than non-carriers of this allele25. The association between this genetic variant
and obesity is inconsistent across epidemiologic studies, although most studies reported that
individuals who harbored the Pro7-allele had a greater body mass index (BMI) than those
who did not.25,26,29,33 In a case-control study, the variant allele (Pro7-allele) conferred an
increased risk of follicular lymphoma.29 The present study showed that subjects who were
heterozygous or homozygous for the Pro7-allele had a 60% lower risk of pancreatic cancer
than those who were homozygous for the Leu7-allele. This finding is not in line with the
functional impact of the NPY rs16139 polymorphism if its effect is only to increase BMI.
This inconsistency may be explained by several factors. Some studies revealed that
increased BMI associated with this polymorphism was not observed among obese or insulin-
resistant individuals,33,34 subgroups with higher risk for pancreatic cancer.8,12 In addition,
NPY was also found to be pleiotropic, i.e. it may affect the development of pancreatic
cancer through mechanisms other than increased BMI. NPY has been found to regulate
energy expenditure, independent of food intake,35 and to modulate immune functions
through its expression in lymphoid tissue and the expression of its receptors in immune
cells.36
ADRB2 is a member of the G protein-coupled adrenergic receptor superfamily and
participates in the peripheral regulation of energy expenditure.14 Expressed in abdominal
subcutaneous adipose tissue, ADRB2 mobilizes lipids within human fat cells by stimulating
lipolysis.30,37 A common polymorphism in ADRB2 (rs1042713) leads to an amino acid
substitution at codon 16 (Gly16Arg).14 Experimental studies have demonstrated that this
sequence variant altered the function of the beta-2 adrenoceptor.38 It has been reported that
subjects carrying the Gly16 allele exhibited a fivefold increased agonist sensitivity in
absence of any change in the expression of this receptor.38 Epidemiologic studies have
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observed the associations of this polymorphism with obesity, diabetes, and plasma lipid
levels, but results are not entirely consistent.16 In one study, the Arg16 allele was associated
with an increased BMI after adjustment for demographic variables, blood lipids, and
diabetes.39 In another study, individuals with two copies of the Arg16 allele had an 87%
higher risk of diabetes than those with zero or one copy of this allele.37 In the present study,
we found that heterozygosity or homozygosity of the Arg16 allele was associated with a
52% elevated risk of pancreatic cancer, as compared with homozygosity of the Gly16 allele.
This association was statistically significant and consistent with the findings of previous
epidemiologic studies that identified the Arg16 allele as a risk factor for obesity and
diabetes.37,39
We also examined the effect of polymorphisms in other genes involved in the regulation of
energy intake [LEP (rs7799039), LEPR (rs1137101), and GHRL (rs696217)] and energy
expenditure [ADRB3 (rs4994) and UCP3 (rs1800849)] on pancreatic cancer risk (Table 2).
None of these polymorphisms was significantly associated with the risk of pancreatic
cancer. Accumulating evidence suggests that these genetic variants are functional because
each of them is associated with either altered levels of protein (e.g. LEP)40 or risk of weight
gain or obesity.41–44 Although none of these SNPs has been evaluated in relation to
pancreatic cancer risk in previous epidemiologic studies, a LEPR polymorphism
(rs1137101) significantly modulated the risk of breast cancer.45 A possible explanation for
our observed null associations with the aforementioned SNPs is that the effects of these
SNPs might be modest and could not be detected due to the relatively small sample size of
the present study.
There are some limitations inherent in the present study. Response rates for both cases and
controls were less than 60%. Selection bias might have occurred due to the low response
rate. It is unlikely that control respondents were significantly different from non-respondents
with regard to the allele frequencies of candidate genes. However, if survival in cases is
related to any of the SNPs considered or their associated phenotypes, our findings could be
altered. Genotyping error should be considered in any genetic association studies. As stated
above, all seven SNPs examined were in Hardy-Weinberg Equilibrium, and 10% of
replicated DNA samples were 100% concordant, which suggests that genotyping error, if
any, should be small in our study. The two polymorphisms significantly associated with
pancreatic cancer risk in this study may simply be markers that are in linkage disequilibrium
with unmeasured polymorphisms that are causally associated with this disease. BMI was not
collected in this study due to an oversight, which precludes us from testing its interactions
with the SNPs examined on pancreatic cancer risk. The lack of BMI data is not viewed as a
limitation for analysis of the genetic variants and pancreatic cancer because BMI, like
energy intake, physical activity, and diabetes, may be on the causal pathway between the
selected SNPs and pancreatic cancer and therefore should not be treated as a potential
confounder in constructed logistic regression models.
In summary, the present study revealed that two polymorphisms in the genes regulating
energy homoeostasis are associated with an altered risk of pancreatic cancer. If confirmed
by other epidemiologic studies, these findings lend further support to the role of obesity and
diabetes in the etiology of this malignancy and underscore the importance of preventing
these conditions as strategies for its primary prevention.
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Table 1
Characteristics of cases and controls in a population-based case-control study of pancreatic cancer in
Minnesota, 1994–1998*
Characteristic Cases (n=173) Controls (n=476) P value
Age (years)† 66.2 (11.4) 65.6 (12.4) 0.54
Sex
  Male 103 (59.9%) 271 (56.9%)
  Female 69 (40.1%) 205 (43.1%) 0.50
Education
  Some high school or less 25 (14.5%) 53 (11.1%)
  High school graduate 66 (38.4%) 121 (25.4%)
  Some college or more 81 (47.1%) 302 (63.5%) 0.0008
Physical activity (hour/week) † 43.6 (26.6) 50.2 (25.6) 0.009
Cigarette smoking
  Never smoker 69 (41.8%) 219 (46.0%)
  Former smoker 70 (42.4%) 203 (42.7%)
  Current smoker 26 (15.8%) 54 (11.3%) 0.30
Alcohol intake (serving/week)† 3.4 (7.0) 4.7 (8.5) 0.08
Energy intake (kcal/day) † 2,106 (967) 2,102 (834) 0.96
Diabetes‡
  Yes 14 (8.1%) 5 (1.1%)
  No 159 (91.9%) 471 (98.9%) <0.0001
*
Data for some variables were missing for cases and/or controls.
†Values given are mean (standard deviation).
‡
Defined as diabetes diagnosed ≥2 years prior to pancreatic cancer diagnosis
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